All In Biotech

Drug Trial Radar · NCT01480076

Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis

An Open-Label, Multicenter, Multinational Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) 10 mg Twice Daily on Quality of Life as Reported by Subjects With Multiple Sclerosis

Last checked: Nov 20, 2026Latest source record: Mar 21, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

901

Actual

Start

Feb 2012

Primary completion

Jul 2013

Study completion Aug 2013

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
First posted
Nov 28, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to assess the effect of long-term treatment with prolonged-release fampridine (BIIB041) 10 mg twice daily on the physical component scale (PCS) of the Short Form 36 Health Status Questionnaire (SF-36) as reported by treatment responders. The secondary objectives of this study are to compare the change in the PCS of the SF-36 between treatment responders and non-responders, to evaluate change from baseline in additional quality of life measures among treatment responders as well as changes from baseline in treatment responders versus non-responders and to assess the safety and tolerability of prolonged-release fampridine 10 mg twice daily.

Conditions

  • Multiple Sclerosis

Interventions

  • FampridineDrug

    Supplied as a 10 mg twice daily tablet and taken twice daily. Doses must be spaced at least 12 hours apart.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in the Physical Component Scale (PCS) of the Short Form 36 Health Status Questionnaire (SF-36) At Months 3, 6, 9, and 12: RespondersTime frame: Baseline, Months 3, 6, 9, 12

Locations

59 sites in 9 countries. Site status is shown where the registry gives one.

  • Research Site

    Concord, New South Wales, Australia

  • Research Site

    Kogarah, New South Wales, Australia

  • Research Site

    Liverpool, New South Wales, Australia

  • Research Site

    New Lambton Heights, New South Wales, Australia

  • Research Site

    Auchenflower, Queensland, Australia

  • Research Site

    Box Hill, Victoria, Australia

  • Research Site

    Clayton, Victoria, Australia

  • Research Site

    Fitzroy, Victoria, Australia

  • Research Site

    Heidelberg, Victoria, Australia

  • Research Site

    Brasschaat, Belgium

  • Research Site

    Brussels, Belgium

  • Research Site

    Diepenbeek, Belgium

  • Research Site

    Fraiture-en-Condroz, Belgium

  • Research Site

    Ghent, Belgium

  • Research Site

    Liège, Belgium

  • Research Site

    Melsbroek, Belgium

  • Research Site

    Overpelt, Belgium

  • Research Site

    Sijsele-Damme, Belgium

  • Research Site

    Wilrijk, Belgium

  • Research Site

    Copenhagen, Denmark

  • Research Site

    Paris, France

  • Research Site

    Nice, Alpes-Maritimes, France

  • Research Site

    Strasbourg, Bas-Rhin, France

  • Research Site

    Caen, Calvados, France

  • Research Site

    Bordeaux, Gironde 5, France

  • Research Site

    Rennes, Ille-et-Vilaine, France

  • Research Site

    Nantes, Loire-Atlantique 6, France

  • Research Site

    Reims, Marne, France

  • Research Site

    Clemont-Ferrand, Rhone, France

  • Research Site

    Paris, Seine-Saint-Denis 14, France

  • Research Site

    Amiens, Somme, France

  • Research Site

    Berlin, Germany

  • Research Site

    Erbach im Odenwald, Germany

  • Research Site

    Hamburg, Germany

  • Research Site

    Jena, Germany

  • Research Site

    Osnabrück, Germany

  • Research Site

    Schwendi, Germany

  • Research Site

    Heidenheim, Bad Wuerttemberg, Germany

  • Research Site

    Kassel, Hesse, Germany

  • Research Site

    Oldenburg, Lower Saxony, Germany

Showing 40 of 59 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.